May 5 2011 Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011

May 5 2011 Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011

MALVERN, Pa.–(BUSINESS WIRE)– Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) will be presented at the 2011 American Thoracic Society International Conference (ATS 2011), being held May 13-18, 2011 in Denver, CO. The poster presentation includes clinical data from a completed Phase 1 study of PRM-151 that evaluated comprehensive safety endpoints and exploratory biomarker activity in healthy subjects and IPF patients. The data to be presented highlight the safety, tolerability, and biomarker activity of Pentraxin-2 therapeutics in patients with idiopathic pulmonary fibrosis (IPF).

See full article at:

http://www.fiercebiotech.com/press-releases/promedior-present-clinical-data-prm-151-rhptx-2-idiopathic-pulmonary-fibros

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>